MedTrace Logo

UK Ibrance Patient Program (IPP) Study

NCT03921866 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2023-03-17

Study results available
· View outcomes & findings →

Summary

What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer treated as part of the IPP?

Conditions

  • HR+/HER2- Locally Advanced, Metastatic Breast Cancer

Interventions

DRUG

Palbociclib

Palbociclib

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2021-03-04
Completion
2021-03-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03921866 on ClinicalTrials.gov